uniQure
Manufacturing · Netherlands · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Paasheuvelweg 25, Amsterdam, North Holla...Phone Number
+31 202406000Website
www.uniqure.comRevenue
$18.1 MillionStock Symbol
QUREIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About uniQure
Founded in 1998 and headquartered in Amsterdam, Netherlands, uniQure is a biotechnology company specializing in gene therapy development. The company focuses on creating innovative single-treatment solutions for patients with severe genetic diseases and disorders. uniQure leverages advanced research and development capabilities to design therapeutic interventions that address the root causes of genetic conditions. With operations across Europe and North America, the company maintains a strong scientific team dedicated to advancing gene therapy technologies and bringing transformative treatments to market.Explore more
uniQure Org Chart
LL
Senior Director, Clinical Research & Developm...
JM
Global Director, QC Technical Services
AV
Director, Product Planning
DM
Associate Director, Statistical Programming
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is uniQure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if uniQure had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at uniQure
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on uniQure recently announced quarterly report
Check out if uniQure is spiking on competitors!
Check if uniQure has recently received funding, and reach out quickly before it becomes old news!
uniQure, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when uniQure launches new products
Funding: Get notified immidiatlly once uniQure has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
uniQure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
uniQure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about uniQure.
uniQure financials insights
Gather financial insights about uniQure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$58M
2014
Stock Offering
$91.8M
Debt
$10M
2015
Stock Offering
$83.2M
Share Placement
$37.6M
2017
Stock Offering
$85.3M
2018
Stock Offering
$147.5M
2019
Stock Offering
$242.8M
uniQure Tech Stack
A closer look at the technologies used by uniQure
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance
Project
uniQure has identified a meaningful total addressable market for its Huntington's disease therapy across tier 1 and tier 2 countries including the UK, Gulf states, Commonwealth nations, and Latin America encompassing tens of thousands of patients, with the UK alone having an estimated prevalence of approximately 7,000 patients, accessible through Named Patient Programs and early access pathways.
Pharmaceuticals
Project
uniQure has stated that the requirement for a sham-controlled study for its one-time surgically infused Huntington's disease therapy which requires 10 to 12 hours of anesthesia raises distinct patient risk, burden, and ethical considerations compared to oral therapies, and that the Enroll-HD natural history registry, comprising 30,000 participants and of regulatory-grade quality, represents a viable alternative basis for evaluation.
Medical Research, Clinical Operations
Project
uniQure has reported that FDA feedback from its Type A and pre-BLA meetings centered on the lack of pre-specification in its analysis.
Compliance, Pharmaceuticals
Project
Medical Research
uniQure News & Media
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additionalUniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. UniQure N.V. (NASDAQ:QURE) is among the best healthcare stocks. TheFly reported on June 18 that Barclays raised its rating on QURE to Overweight from Equal Weight and increased its price target to $65 from $25. The firm viewed […]uniQure Announces Pricing of Upsized $225 Million Public Offering
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenuniQure Announces $150 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding uniQure
Sign Up For FreeTo access detailed company insights
Founded in 1998 and headquartered in Amsterdam, Netherlands, uniQure is a biotechnology company specializing in gene therapy development. The company focuses on creating innovative single-treatment solutions for patients with severe genetic diseases and disorders. uniQure leverages advanced research and development capabilities to design therapeuti... Read More
